Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model.

Garaiman, Alexandru; Steigmiller, Klaus; Gebhard, Catherine; Mihai, Carina; Dobrota, Rucsandra; Bruni, Cosimo; Matucci-Cerinic, Marco; Henes, Joerg; de Vries-Bouwstra, Jeska; Smith, Vanessa; Doria, Andrea; Allanore, Yannick; Dagna, Lorenzo; Anić, Branimir; Montecucco, Carlomaurizio; Kowal-Bielecka, Otylia; Martin, Mickael; Tanaka, Yoshiya; Hoffmann-Vold, Anna-Maria; Held, Ulrike; ... (2023). Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. Rheumatology, 62(SI), SI91-SI100. Oxford University Press 10.1093/rheumatology/keac405

Text Use_of_platelet_inhibitors_for_digital_ulcers_related_to.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (773kB)

OBJECTIVE

To develop and validate the prognostic prediction model DU-VASC to assist the clinicians in decision-making regarding the use of platelet inhibitors (PIs) for the management of digital ulcers in patients with systemic sclerosis. Secondly, to assess the incremental value of PIs as predictor.

METHODS

We analysed patient data from the European Scleroderma Trials and Research group registry (one time point assessed). Three sets of derivation/validation cohorts were obtained from the original cohort. Using logistic regression, we developed a model for prediction of digital ulcers (DUs). C-Statistics and calibration plots were calculated to evaluate the prediction performance. Variable importance plots and the decrease in C-statistics were used to address the importance of the predictors.

RESULTS

Of 3710 patients in the original cohort, 487 had DUs and 90 were exposed to PIs. For the DU-VASC model, which includes 27 predictors, we observed good calibration and discrimination in all cohorts (C-statistic = 81.1% [95% CI: 78.9%, 83.4%] for the derivation and 82.3% [95% CI: 779.3%, 85.3%] for the independent temporal validation cohort). Exposure to PIs was associated with absence of DUs and was the most important therapeutic predictor. Further important factors associated with absence of DUs were lower modified Rodnan skin score, anti-Scl-70 negativity and normal CRP. Conversely, the exposure to phosphodiesterase-5 inhibitor, prostacyclin analogues or endothelin receptor antagonists seemed to be associated with the occurrence of DUs. Nonetheless, previous DUs remains the most impactful predictor of DUs.

CONCLUSION

The DU-VASC model, with good calibration and discrimination ability, revealed that PI treatment was the most important therapy-related predictor associated with reduced DU occurrence.

Interest & Impact

Downloads

1 since deposited on 04 Jan 2024
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item